leadf
logo-loader
viewPharmaxis Ltd
(
ASX:PXS
)

Pharmaxis updates on bone marrow cancer trial and talks potential of PXS-5505 in liver cancer

Pharmaxis Ltd (ASX:PXS)'s Gary Phillips tells Proactive the third dose cohort in the phase 1c clinical trial for the drug PXS‐5505 as a potential new treatment for the bone marrow cancer myelofibrosis is already fully recruited and dosing of all patients is expected to commence at participating sites in Australian and South Korean hospitals shortly. He also discusses the first public presentation of data from a preclinical study of PXS-5505 in the liver cancer, cholangiocarcinoma (CCA) at the Americas Hepato-Pancreato-Biliary Association (AHBPA) conference in Miami, USA.

Quick facts: Pharmaxis Ltd

Follow
ASX:PXS

Price: 0.145 AUD

Market Cap: $65.79 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Pharmaxis hails positive results in Phase 1 scarring trial

Pharmaxis Ltd (ASX:PXS)'s Gary Phillips speaks to Proactive following the news its novel topical drug treatment for scarring has delivered positive phase 1 clinical trial results and will now advance to the next stage of development in patients. He says in a study of healthy volunteers PXS‐6302...

2 weeks, 6 days ago

2 min read